Drug Prices
Pending federal approval, Civica Rx, the nonprofit consortium of U.S. hospitals, plans to manufacture and distribute several generic insulins, continuing its mission to alleviate chronic shortages of inpatient drugs and reduce drug prices.
Drug companies raised prices faster than inflation for about half of all drugs covered by Medicare between July 2019 and July 2020, according to an analysis released last week by the Kaiser Family Foundation.
The Centers for Medicare & Medicaid Services Dec.
The administration issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug coverage and spending, including the most frequently dispensed and costliest drugs, and information on prescription drug rebates and their impact on premiums…
In addition to being based on a very small sample size, a recently published study on hospital costs for clinician-administered drugs under Medicare Part B does not provide direct insight as to what hospitals actually pay to acquire these drugs, writes Aaron Wesolowski, vice president of policy…
The authors of a recent analysis published in JAMA themselves acknowledge that their sample size is very small, making it hard to draw any sweeping conclusions based on their data. In addition, the study does not provide direct insight as to what hospitals actually pay to acquire these drugs.
The AHA 340B Advocacy Alliance Nov. 17 at 3 p.m. ET will host a special call for AHA 340B hospital members to provide an update on the latest activity on the 340B Drug Pricing Program.
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.
Walmart recently partnered with the consumer-facing health care platform Transcarent to provide low-cost prescription drugs, telehealth, optical and other services to self-insured employers.
This letter to CMS reiterates AHA’s position that the agency’s Most Favored Nation Proposed Rule should be withdrawn.